Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.40

+5.5%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2499)	6/11/2009 11:08:22 PM
From: Jibacoa	Read Replies (2) of 3722

VICL was up 22.12% and continued to do well AHs. The volume of 2,574,235 was about 8x its ADV. bigcharts.marketwatch.com It presented today at 8th Annual Needham Life Sciences Conference in N.Y. and earlier this week at the Noble Financial Group Fifth Annual Equity Conference, here in Holywood, FL. <g> And on May 27 it gave an update on its Influenza Vaccine and an Overview of the PIII of its Allovectin-7 for treatment of Metastatic Melanoma at the ASGT Conference in San Diego. It also announced last week the issuance of U.S. Patent covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses. Vical has patented a new influenza vaccine approach based on portions of the virus which are much more consistent between strains than the constantly changing conventional vaccine target, hemagglutinin (HA), and which are highly conserved even between seasonal and potentially pandemic emerging strains. Its DNA vaccine technology can induce both antibody and T-cell immune responses against the target portions of the virus, potentially providing a level of protection not available with conventional influenza vaccines. In addition, a vaccine based on this approach may have the potential to provide protection against future pandemic threats from new strains of influenza viruses. On the 1stQ (March) it was able to trim some its loss on 16% improvement on revenues. The EL for 2009 is around $0.70 vs. $0.93 in 2008. It trades around 1.9xBV with no significant LTD It has resistance at the $3 level before it can retest its Apr27 H at $3.30 <g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next